Document is current
Any future updates will be listed below
-
Authors
Zhang, Jia-Yuan
Whalley, Justin P.
Knight, Julian C.
Wicker, Linda S.
Todd, John A.
Ferreira, Ricardo C. http://orcid.org/0000-0001-5733-3285
-
Funding
Funding for this research was provided by:
Juvenile Diabetes Research Foundation United States of America (1-SRA-2019-657-A-N, 4-SRA-2017-473-A-A)
Wellcome (107212/A/15/Z)
Wellcome Trust (203141/Z/16/Z)
China Scholarship Council-University of Oxford Scholarship
- License Information
-
More Information
Article History
Received: 27 February 2023
Accepted: 4 September 2023
First Online: 12 September 2023
Declarations
:
: The studies referred in this manuscript were performed in accordance with the guidelines for good clinical practice and the Declaration of Helsinki. All participants provided written informed consent prior to their participation in the studies. Approval for the Adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency) was obtained from the Health Research Authority, National Research Ethics Service (14/EE/1057), London, United Kingdom, and the trial was registered at the International Standard Randomised Controlled Trial Number Register (ISRCTN40319192) and ClinicalTrials.gov (NCT02265809). For the COMBAT and INCOV studies, relevant study approval and detailed participant selection information is provided in the respective original publications [CitationRef removed, CitationRef removed].
: Not applicable.
: J.A.T. is a member of the Scientific Advisory Boards of GSK, Vesalius Therapeutics and Precion. The remaining authors declare no competing interests.
